NBRV - Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta
- Nabriva Therapeutics ( NASDAQ: NBRV ) signed a distribution agreement with Er-Kim for the oral and intravenous formulations of its medicine Xenleta (lefamulin).
- Xenleta is used to treat adults with community-acquired bacterial pneumonia.
- Under the agreement, Er-Kim gains exclusive rights to distribute Xenleta in Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia.
- Ireland-based Nabriva said Er-Kim also may distribute the drug to an additional five countries through a Named Patient Usage (NPU) program.
- Nabriva noted that it will be the exclusive supplier of the therapy to Er-Kim.
- NBRV +19.12% to $0.23 premarket July 18
For further details see:
Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta